Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Tvardi Therapeutics, Inc. - Common Stock (NQ:TVRD)

3.768 +0.028 (+0.75%)
Streaming Delayed Price Updated: 11:56 AM EST, Feb 25, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Tvardi Therapeutics, Inc. - Common Stock

Get insights into the top gainers and losers of Wednesday's pre-market session. ↗
Via Chartmill
News headline image
Unusual volume stocks in Monday's session ↗
In today's session, these stocks are experiencing unusual volume. 
Via Chartmill
News headline image
In today's session, these stocks are experiencing unusual volume. ↗
Unusual volume stocks are being observed in Thursday's session. 
Via Chartmill
News headline image
Unusual volume stocks in Wednesday's session ↗
Which stocks have an unusual volume on Wednesday? 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Tvardi Therapeutics' Lung Disease Candidate Fails To Show Any Clinical Benefit, Stock Sinks ↗
Tvardi Therapeutics stock falls as Phase 2 IPF trial of TTI-101 shows no significant FVC improvement, with high variability and placebo response. 
Via Benzinga
News headline image
Gold Rises Over 3%; Tvardi Therapeutics Shares Plunge ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
Dow Surges 1%; Fastenal Shares Fall After Q3 Results ↗
 
Via Benzinga
Topics Stocks
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Did Tvardi Therapeutics Stock Plummet 87% Pre-Market Today? ↗
The company said that its investigational drug did not meet its goal in a study, and no statistically significant differences between placebo and treatment arms were observed after preliminary review... 
Via Stocktwits
News headline image
Tvardi Posts Q2 Net Income Turnaround ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Recently Listed Tvardi Therapeutics' Lead Drug 'Positioned To Drive Broad Improvement', Analyst Sees Over 150% Stock Upside ↗
Tvardi advances fibrosis drug TTI-101 in IPF and liver cancer as Piper initiates with $78 target; merger boosts cash runway into late 2026. 
Via Benzinga
News headline image
This Modine Manufacturing Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Coursera Shares Are Trading Higher By Over 7%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.